

## (Annexure 14)

## Project Extension form अखिल भारतीय आयुर्वेद संस्थान All INDIA INSTITUTE OF AYURVEDA (AIIA)

EC Ref. No. (for office use):

\*The project extension must be duly submitted no later than 30 days before the approval expires.

T	Title of study:						
F	Principal Investigator (Name, Designation and Affiliation)						
	T	<u></u>					
1.	EC Reference No:						
2.	Date of EC Approval: Click here to enter a date.	Duration of Approval months/ years					
3.	Date of Start of study: Click here to enter a date.	Date of Completion: Click here to enter a date.  (As per the first approval granted)					
	Duration of Extension sought: months/ years	( a per me) mer approval grames y					
	Period of Extension sought from Click here to enter a date.	To Click here to enter a date.					
4.	Have there been any modifications in the budget for the ex	fications in the budget for the extension sought?					
	If No, skip to item no.5	Yes ☐ No☐					
	If yes, discuss in detail:						
5.	Does the study involve recruitment of participants?	Yes No No					
	(a) If yes, Total number for study No.						
	(b) Screened: No. Enrolled: No.						
	(c) Number Completed: No. on followup: No.						
	(d) Enrolment status – ongoing / completed/ stopped No.						
	(e) If ongoing, Expected No.						
	<ul> <li>(f) Report of DSMB*</li> <li>* In case there is a Data Safety Monitoring Board (DSMB) for the study provide a c</li> <li>(g) Any other remark</li> </ul>	Yes No NALL Copy of the report from the DSMB. If not write NA.					
	(h) Have any participants withdrawn from this study since If yes, total number withdrawn and reasons:	the last approval? Yes 🔲 No 🔲 NA 🔲					

	6.	Have there been any amendments in the research protocol/informed consent document (ICD) for the				
		extension sought?	Yes No			
		If No, skip to item no.7				
		(a) If yes, discuss in detail:				
=		(b) In case of amendments in the research protocol/ICD, will re-cons	sent he sought from			
		participants?				
		If yes, when / how:	Yes No			
7.		Is any new information available that changes the benefit -risk analysis o	of human participants			
,.			Yes No			
		involved in this study?	Yes 🗀 No 🗀			
•		If yes, discuss in detail:				
8.		Have any ethical concerns occurred during the study?	Yes 🔲 No 🔲			
		If yes, give details				
9.		(a) Have any adverse events been noted since the last review?	Yes 🔲 No 🔲			
		Describe in brief:				
		(b) Have any SAE's occurred since last review?	Yes 🔲 No 🔲			
		If yes, number of SAE's: Type of SAE's:				
		(c) Is the SAE related to the study?	Yes No No			
		Have you reported the SAE to EC? If no, state reasons	Yes 🔲 No 🔲			
10	).	Has there been any protocol deviations/violations that occurred during the	he period of study?			
		If yes, number of deviations				
		Have you reported the deviations to EC? If no, state reasons	Yes 🔲 No 🔲			
11		In case of multicentric trials, whether reports of off-site SAEs have been s	submitted to the EC			
			Yes 🔲 No 🔲 NA 🔲			
12		Are there any publications or presentations during this period? If yes give	e details Yes 🔲 No 🔲			

13.	Briefly explain the reason for the extension sought (up to 500 words) (Please attach the relevant documents in support of the extension.)				
	Signature of PI:			Click here to enter a date.	